PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7:
A61K 9/51, 31/192, 9/10

A1

(11) International Publication Number: WO 00/09096
(43) International Publication Date: 24 February 2000 (24.02.00)

(21) International Application Number: PCT/US99/18270

(22) International Filing Date: 12 August 1999 (12.08.99)

(30) Priority Data:

09/154,422 13 August 1998 (13.08.98) US

(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application

US 09/154,422 (CIP)
Filed on 13 August 1998 (13.08.98)

(71) Applicant (for all designated States except US): NANOSYSTEMS [US/US]; 3000 Horizon Drive, King of Prussia, PA 19406 (US).

(72) Inventors; and

- (75) Inventors/Applicants (for US only): LEE, Robert [US/US]; 1335 Roberts Road, Gilbertsville, PA 19525 (US). DE CASTRO, Lan [US/US]; 44 Plymouth Street, Montclair, NJ 07042 (US).
- (74) Agents: SCHAFER, Michele, M. et al.; Foley & Lardner, Suite 500, 3000 K Street, N.W., Washington, DC 20007-5109 (US).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: INJECTABLE FORMULATIONS OF NANOPARTICULATE NAPROXEN

(57) Abstract

Described are an injectable formulation of nanoparticulate naproxen that produces minimal or no pain or burning sensation upon administration, and methods of making and using such a formulation. The injectable formulation comprises nanoparticulate naproxen having a povidone polymer adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than about 600 nm.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Paso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	iE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of Americ
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	zw	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

INJECTABLE FORMULATIONS OF NANOPARTICULATE NAPROXEN

BACKGROUND OF THE INVENTION

5

10

20

Field of the Invention

The present invention is directed to an injectable formulation of nanoparticulate naproxen that produces minimal or no intramuscular pain or burning sensation upon administration, methods of making such a formulation, and methods of using such a formulation.

Description of the Related Art

Naproxen, also known as 6-methoxy-α-methyl-2-napthalene-acetic acid and d-2(6-methoxy-2-naphthyl)propionic acid, is a well-known anti-inflammatory,
analgesic, and antipyretic agent. It has been approved in many countries around the world for almost two decades and has a very safe risk-benefit profile. It is sold under the trade names ALEVE®, ANAPROX®, NAPROSYN®, and SYNFLEX® (all available from Syntex Chemicals, Inc.). See The Merck Index, 10th Edition, pp. 6274 (Merck & Co., Rahway, NJ, 1983).

Naproxen, which is highly water insoluble, *i.e.*, less than 10 mg/ml, has the following chemical structure:

Naproxen is a non-steroidal anti-inflammatory drug (NSAID) often used to relieve the inflammation, swelling, stiffness, and joint pain associated with rheumatoid arthritis, osteoarthritis (the most common form of arthritis), juvenile arthritis, ankylosing spondylitis (spinal arthritis), tendinitis, bursitis, and acute gout. In addition, it is used to treat pain associated with menstrual periods, migraine headaches, and other types of mild to moderate pain.

Naproxen acts by suppressing the production of prostaglandins, which are hormone-like substances that act on local tissues to produce pain and inflammation. Its pharmaceutical forms of delivery include tablets, capsules, and liquids. Delivery characteristics and forms are disclosed in, for example, U.S. Patent Nos. 3,904,682; 4,009,197; 4,780,320; 4,888,178; 4,919,939; 4,940,588; 4,952,402; 5,200,193; 5,354,556; 5,462,747; and 5,480,650, all of which are specifically incorporated by reference. The synthesis of naproxen is described in U.S. Patent Nos. 3,904,682 and 4,009,197.

10

15

20

25

Naproxen is a more potent pain reliever than aspirin, especially for menstrual cramps, toothaches, minor arthritis, and injuries accompanied by inflammation, such as tendinitis. The naproxen sodium salt is specifically indicated in the treatment of various types of acute and very high intensity pain because it induces a rapid and sustained remission. In addition, it is possible to obtain a good analgesic effect with few administrations, due to naproxen's particular pharmacokinetics. Tablet formulations of naproxen were approved for OTC ("over the counter" as compared to prescription) marketing by the U.S. Food and Drug Administration in 1994.

Because of naproxen's low solubility, it is generally formulated for oral administration. However, oral administration of naproxen frequently results in gastrointestinal irritation. All NSAIDs produce gastrointestinal symptoms to some degree upon oral administration. Such symptoms most commonly are constipation, gastric burns, diarrhea, stomatitis, dyspepsia, nausea, vomiting, upper abdominal

pain, and heartburn. Oral administration may also lead to an ulcer or bleeding from the stomach or duodenum.

Gastrointestinal irritation resulting from oral administration of an NSAID can be significant. Numerous literature articles detail the severity of gastric irritation caused by NSAID compositions. For example, one report states that between 10,000 and 20,000 people in Canada each year are hospitalized with major gastro-intestinal bleeding caused by oral ingestion of NSAIDs, with effects resulting in death for at least 1,000 of these patients. *See Marketplace*, October 24, 1996. Yet another reference states that gastrointestinal complications of NSAID use may be responsible for over 10,000 deaths each year. See *American Family Physician*, March 1997.

5

10

15

20

25

Injectable formulations of naproxen are preferable over oral administration forms for several reasons. First, such formulations can lessen or eliminate side effects of gastro-intestinal irritation. Second, intravenous (IV) or intramuscular (IM) administration of a drug results in a significantly shorter response time as compared to oral administration. Moreover, injectable formulations of pain medication are also preferable for post-operative health care, where oral administration may not be feasible. Injectable formulations of naproxen are particularly preferred, as naproxen is not addictive, in contrast to other injectable formulations of drugs, such as morphine and ketorolac (Toradol®).

Injectable formulations of naproxen have been used prior to the present invention. See Marsala et al., "Treatment of Acute Pain of Ureteral and Biliary Colic with Naproxen Sodium Administered by the Parenteral Route," Int. J. Clin. Pharmacol. Res., 6:495-500 (1986) (IM and IV injections of naproxen); L. Kvarnes, "Naproxen Sodium Versus Pentazocine in Treating Postoperative Pain," Curr. Ther. Res., Clin. Exp., 46:259-268 (1989) (IM injections of naproxen). However, injectable naproxen formulations are difficult to formulate due to the low solubility of naproxen. Moreover, current injectable formulations of naproxen are undesirable because they produce intense pain and/or a burning sensation upon administration.

Such pain is counter-productive, particularly as the patient to be treated is generally already suffering from intense pain. Thus, the pain upon administration interferes with patient treatment, and has led to the use of alternative, but less desirable, injectable pain medications.

There is currently a need for a safe and effective injectable formulation of naproxen that produces minimal or no pain or burning sensation upon administration. In addition, there is a need in the art for methods of making and methods of using such naproxen formulations. The present invention satisfies these needs.

5

10

15

20

25

SUMMARY OF THE INVENTION

The present invention is directed to the surprising and unexpected discovery of a new injectable formulation of naproxen that produces minimal or no pain or burning sensation upon administration. The injectable formulation comprises nanoparticulate naproxen having a povidone polymer adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than about 600 nm. Preferably, the effective average particle size of the nanoparticulate naproxen is less than about 450 nm, more preferably less than about 300 nm, even more preferably less than about 250 nm, and most preferably less than about 100 nm. Nanoparticulate compositions were first described in U.S. Patent No. 5,145,684 ("the '684 patent"), which is specifically incorporated herein by reference.

The invention provides for compositions comprising high naproxen concentrations in low injection volumes, with rapid drug dissolution upon administration.

In another aspect of the invention there is provided a method of preparing injectable nanoparticulate naproxen formulations. The method comprises: (1) dispersing naproxen in a liquid dispersion medium comprising a povidone polymer with a molecular weight of less than about 40,000 daltons; and (2) mechanically reducing the particle size of the naproxen to an effective average particle size of less

than about 600 nm. Preferably, the pH of the liquid dispersion medium is maintained within the range of from about 3 to about 8 during the size reduction process.

Yet another aspect of the present invention provides a method of treating a mammal requiring anti-inflammatory, analysesic, or antipyretic treatment comprising administering to the mammal the above-described injectable nanoparticulate naproxen formulation.

5

10

15

20

25

It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory and are intended to provide further explanation of the invention as claimed. Other objects, advantages, and novel features will be readily apparent to those skilled in the art from the following detailed description of the invention.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to the surprising and unexpected discovery of a new injectable formulation of naproxen that produces minimal or no pain or burning sensation upon administration. The injectable composition comprises nanoparticulate naproxen having a povidone polymer with a molecular weight of less than about 40,000 daltons adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than about 600 nm. Preferably, the effective average particle size of the nanoparticulate naproxen is less than about 450 nm, more preferably less than about 300 nm, even more preferably less than about 250 nm, and most preferably less than about 100 nm.

Naproxen has a pKa of 4.4. Below its pKa of 4.4, the solubility of naproxen is about 20 micrograms/ml. However, above a pKa of 4.4, the solubility of naproxen is about 3 mg/ml. It is preferred that the nanoparticulate naproxen/povidone polymer pharmaceutical formulation of the invention has a pH of between about 6 to about 7.

In human therapy, it is important to provide a naproxen dosage form that delivers the required therapeutic amount of the drug *in vivo*, and that renders the drug bioavailable in a rapid and constant manner. The injectable nanoparticulate naproxen formulations of the present invention satisfies these needs.

5 Povidone Polymers

10

15

20

25

Povidone polymers, also known as polyvidon(e), povidonum, PVP, and polyvinylpyrrolidone, are sold under the trade names Kollidon[®] (BASF Corp.) and Plasdone[®] (ISP Technologies, Inc.). They are polydisperse macromolecular molecules, with a chemical name of 1-ethenyl-2-pyrrolidinone polymers and 1-vinyl-2-pyrrolidinone polymers. Povidone polymers are produced commercially as a series of products having mean molecular weights ranging from about 10,000 to about 700,000 daltons. To be useful as a surface modifier for a drug compound to be administered to a mammal, the povidone polymer must have a molecular weight of less than about 40,000 daltons, as a molecular weight of greater than 40,000 daltons would have difficulty clearing the body.

Povidone polymers are prepared by, for example, Reppe's process, comprising: (1) obtaining 1,4-butanediol from acetylene and formaldehyde by the Reppe butadiene synthesis; (2) dehydrogenating the 1,4-butanediol over copper at 200° to form γ-butyrolactone; and (3) reacting γ-butyrolactone with ammonia to yield pyrrolidone. Subsequent treatment with acetylene gives the vinyl pyrrolidone monomer. Polymerization is carried out by heating in the presence of H₂O and NH₃. See The Merck Index, 10th Edition, pp. 7581 (Merck & Co., Rahway, NJ, 1983).

The manufacturing process for povidone polymers produces polymers containing molecules of unequal chain length, and thus different molecular weights. The molecular weights of the molecules vary about a mean or average for each particular commercially available grade. Because it is difficult to determine the polymer's molecular weight directly, the most widely used method of classifying

various molecular weight grades is by K-values, based on viscosity measurements. The K-values of various grades of povidone polymers represent a function of the average molecular weight, and are derived from viscosity measurements and calculated according to Fikentscher's formula.

The weight-average of the molecular weight, Mw, is determined by methods that measure the weights of the individual molecules, such as by light scattering.

Table 1 provides molecular weight data for several commercially available povidone polymers, all of which are soluble.

TABLE 1

5

15

20

Povidone	K-Value	Mv (Daltons)**	Mw (Daltons)**	Mn (Daltons)**
Plasdone C-15®	17±1	7,000	10,500	3,000
Plasdone C-30®	30.5 ± 1.5	38,000	62,500*	16,500
Kollidon 12 PF®	11-14	3,900	2,000-3,000	1,300
Kollidon 17 PF®	16-18	9,300	7,000-11,000	2,500
Kollidon 25®	24-32	25,700	28,000-34,000	6,000

^{*}Because the molecular weight is greater than 40,000 daltons, this povidone polymer is not useful as a surface stabilizer for a drug compound to be administered parenterally (i.e., injected).

Based on the data provided in Table 1, exemplary preferred commercially available povidone polymers include, but are not limited to, Plasdone C-15[®], Kollidon 12 PF[®], Kollidon 17 PF[®], and Kollidon 25[®].

7

^{**}Mv is the viscosity-average molecular weight, Mn is the number-average molecular weight, and Mw is the weight average molecular weight. Mw and Mn were determined by light scattering and ultra-centrifugation, and Mv was determined by viscosity measurements.

Injectable Nanoparticulate Naproxen Formulations

The invention provides injectable nanoparticulate naproxen formulations that can comprise high drug concentrations in low injection volumes, with rapid drug dissolution upon administration. Preferred compositions comprise, based on % w/w:

5 – 50%
0.1 - 50%
0.05 - 0.25%
pH about 6 to about 7.
q.s.

10

15

20

25

5

Exemplary preservatives include methylparaben (about 0.18% based on % w/w), propylparaben (about 0.02% based on % w/w), phenol (about 0.5% based on % w/w), and benzyl alcohol (up to 2% v/v). An exemplary pH adjusting agent is sodium hydroxide, and an exemplary liquid carrier is sterile water for injection. Other useful preservatives, pH adjusting agents, and liquid carriers are well-known in the art.

Methods of Making Injectable Naproxen Formulations

In another aspect of the invention there is provided a method of preparing the injectable nanoparticulate naproxen formulations of the invention. The method comprises: (1) dispersing naproxen in a liquid dispersion medium comprising a povidone polymer with a molecular weight of less than about 40,000 daltons; and (2) mechanically reducing the particle size of the naproxen to an effective average particle size of less than about 600 nm. Preferably, the effective average particle size of the nanoparticulate naproxen is less than about 450 nm, more preferably less than about 300 nm, even more preferably less than about 250 nm, and most preferably less than about 100 nm. The pH of the liquid dispersion medium is preferably maintained within the range of from about 5.0 to about 7.5 during the size reduction

process. Preferably, the dispersion medium used for the size reduction process is aqueous.

5

10

Effective methods of providing mechanical force for particle size reduction of naproxen include ball milling, media milling, and homogenization, for example, with a Microfluidizer[®] (Microfluidics Corp.). Ball milling is a low energy milling process that uses milling media, drug, stabilizer, and liquid. The materials are placed in a milling vessel that is rotated at optimal speed such that the media cascades and reduces the drug particle size by impaction. The media used must have a high density as the energy for the particle reduction is provided by gravity and the mass of the attrition media.

Media milling is a high energy milling process. Drug, stabilizer, and liquid are placed in a reservoir and recirculated in a chamber containing media and a rotating shaft/impeller. The rotating shaft agitates the media which subjects the drug to impaction and sheer forces, thereby reducing the drug particle size.

15 Homogenization is a technique that does not use milling media. Drug, stabilizer, and liquid (or drug and liquid with the stabilizer added after particle size reduction) constitute a process stream propelled into a process zone, which in the Microfluidizer® is called the Interaction Chamber. The product to be treated is inducted into the pump, and then forced out. The priming valve of the Microfluidizer® purges air out of the pump. Once the pump is filled with product, 20 the priming valve is closed and the product is forced through the interaction chamber. The geometry of the interaction chamber produces powerful forces of sheer, impact, and cavitation which are responsible for particle size reduction. Specifically, inside the interaction chamber, the pressurized product is split into two 25 streams and accelerated to extremely high velocities. The formed jets are then directed toward each other and collide in the interaction zone. The resulting product has very fine and uniform particle or droplet size. The Microfluidizer[®] also provides

a heat exchanger to allow cooling of the product. U.S. Patent No. 5,510,118, which is specifically incorporated by reference, refers to a process using a Microfluidizer[®] resulting in sub 400 nm particles.

Using a particle size reduction method, the particle size of naproxen is reduced to an effective average particle size of less than about 600 nm. Preferably, the effective average particle size of the nanoparticulate naproxen is less than about 450 nm, more preferably less than about 300 nm, even more preferably less than about 250 nm, and most preferably less than about 100 nm. The naproxen particles can be reduced in size in the presence of a povidone polymer, or the povidone polymer can be added to the naproxen dispersion following particle size reduction.

5

10

15

20

25

Naproxen can be added to a liquid medium in which it is essentially insoluble to form a premix. The concentration of the naproxen in the liquid medium can vary from about 5 to about 60%, and preferably is from about 15 to about 50% (w/v), and more preferably about 20 to about 40%. The povidone polymer can be present in the premix or it can be added to the drug dispersion following particle size reduction. The concentration of the povidone polymer can vary from about 0.1 to about 50%, and preferably is from about 0.5 to about 20%, and more preferably from about 1 to about 10%, by weight.

The premix can be used directly by subjecting it to mechanical means to reduce the average naproxen particle size in the dispersion to less than about 600 nm. It is preferred that the premix be used directly when a ball mill is used for attrition. Alternatively, naproxen and the povidone polymer can be dispersed in the liquid medium using suitable agitation, e.g., a Cowles type mixer, until a homogeneous dispersion is observed in which there are no large agglomerates visible to the naked eye. It is preferred that the premix be subjected to such a premilling dispersion step when a recirculating media mill is used for attrition.

The mechanical means applied to reduce the naproxen particle size conveniently can take the form of a dispersion mill. Suitable dispersion mills

include a ball mill, an attritor mill, a vibratory mill, and media mills such as a sand mill and a bead mill. A media mill is preferred due to the relatively shorter milling time required to provide the desired reduction in particle size. For media milling, the apparent viscosity of the premix is preferably from about 100 to about 1000 centipoise, and for ball milling the apparent viscosity of the premix is preferably from about 1 up to about 100 centipoise. Such ranges tend to afford an optimal balance between efficient particle size reduction and media erosion.

The attrition time can vary widely and depends primarily upon the particular mechanical means and processing conditions selected. For ball mills, processing times of up to five days or longer may be required. Alternatively, processing times of less than 1 day (residence times of one minute up to several hours) are possible with the use of a high shear media mill.

The naproxen particles must be reduced in size at a temperature which does not significantly degrade naproxen. Processing temperatures of less than about 30 to less than about 40°C are ordinarily preferred. If desired, the processing equipment can be cooled with conventional cooling equipment. Control of the temperature, e.g., by jacketing or immersion of the milling chamber in ice water, is contemplated. Generally, the method of the invention is conveniently carried out under conditions of ambient temperature and at processing pressures which are safe and effective for the milling process. Ambient processing pressures are typical of ball mills, attritor mills, and vibratory mills.

Grinding Media

5

10

15

20

25

The grinding media can comprise particles that are preferably substantially spherical in shape, e.g., beads, consisting essentially of polymeric resin.

Alternatively, the grinding media can comprise a core having a coating of a polymeric resin adhered thereon.

In general, suitable polymeric resins are chemically and physically inert, substantially free of metals, solvent, and monomers, and of sufficient hardness and friability to enable them to avoid being chipped or crushed during grinding. Suitable polymeric resins include crosslinked polystyrenes, such as polystyrene crosslinked with divinylbenzene; styrene copolymers; polycarbonates; polyacetals, such as Delrin® (E.I. du Pont de Nemours and Co.); vinyl chloride polymers and copolymers; polyurethanes; polyamides; poly(tetrafluoroethylenes), e.g., Teflon[®](E.I. du Pont de Nemours and Co.), and other fluoropolymers; high density polyethylenes; polypropylenes; cellulose ethers and esters such as cellulose acetate; polyhydroxymethacrylate; polyhydroxyethyl acrylate; and silicone-containing polymers such as polysiloxanes and the like. The polymer can be biodegradable. Exemplary biodegradable polymers include poly(lactides), poly(glycolide) copolymers of lactides and glycolide, polyanhydrides, poly(hydroxyethyl methacylate), poly(imino carbonates), poly(N-acylhydroxyproline)esters, poly(Npalmitoyl hydroxyproline) esters, ethylene-vinyl acetate copolymers, poly(orthoesters), poly(caprolactones), and poly(phosphazenes). For biodegradable polymers, contamination from the media itself advantageously can metabolize in vivo into biologically acceptable products that can be eliminated from the body.

10

15

20

25

The grinding media preferably ranges in size from about 0.01 to about 3 mm. For fine grinding, the grinding media is preferably from about 0.02 to about 2 mm, and more preferably from about 0.03 to about 1 mm in size.

The polymeric resin can have a density from about 0.8 to about 3.0 g/cm³.

In a preferred grinding process the particles are made continuously. Such a method comprises continuously introducing naproxen into a milling chamber, contacting the naproxen with grinding media while in the chamber to reduce the naproxen particle size, and continuously removing the nanoparticulate naproxen from the milling chamber.

The grinding media is separated from the milled nanoparticulate naproxen using conventional separation techniques, in a secondary process such as by simple filtration, sieving through a mesh filter or screen, and the like. Other separation techniques such as centrifugation may also be employed.

5

10

15

20

25

Particle Size

As used herein, particle size is determined on the basis of the weight average particle size as measured by conventional particle size measuring techniques well known to those skilled in the art. Such techniques include, for example, sedimentation field flow fractionation, photon correlation spectroscopy, light scattering, and disk centrifugation. By "an effective average particle size of less than about 600 nm" it is meant that at least 90% of the particles, by weight, have a particle size of less than about 600 nm when measured by the above-noted techniques. In preferred embodiments, the effective average particle size is less than about 450 nm, and more preferably less than about 400 nm. The naproxen particles can also have an effective average particle size of less than about 300 nm, less than about 250 nm, and less than about 100 nm. With reference to the effective average particle size, it is preferred that at least 90%, more preferably at least 95%, and most preferably at least 99% of the particles have a particle size less than the effective average particle size. In particularly preferred embodiments essentially all of the particles have a size less than about 600 nm.

While applicants do not wish to be bound by theoretical mechanisms, it is believed that the povidone polymer hinders the flocculation and/or agglomeration of the naproxen particles by functioning as a mechanical or steric barrier between the particles, minimizing the close, interparticle approach necessary for agglomeration and flocculation.

Method of Treatment

5

10

15

Yet another aspect of the present invention provides a method of treating a mammal, including a human, requiring anti-inflammatory, analgesic, or antipyretic treatment comprising administering to the mammal the injectable nanoparticulate naproxen formulation of the invention. Particularly advantageous features of the present invention include that the pharmaceutical formulation of the invention exhibits unexpectedly rapid drug absorption upon administration, and produces minimal or no pain or irritation upon administration. In addition, the injectable formulation of the invention can provide a high naproxen concentration in a small volume to be injected. A general protocol for administration comprises a bolus injection of naproxen, with one continuous fast injection, rather than a slow infusion of the drug.

Sterile Product Manufacturing

Development of injectable compositions requires the production of a sterile product. The manufacturing process of the present invention is similar to typical known manufacturing processes for sterile suspensions. A typical sterile suspension manufacturing process flowchart is as follows:

(Media Conditioning)

↓

Compounding

↓

Particle Size Reduction

Vial Filling

↓

(Lyophilization) and/or (Terminal Sterilization)

As indicated by the optional steps in parentheses, some of the processing is dependent upon the method of particle size reduction and/or method of sterilization. For example, media conditioning is not required for a milling method that does not use media. If terminal sterilization is not feasible due to chemical and/or physical instability, aseptic processing can be used.

The following examples are given to illustrate the present invention. It should be understood, however, that the invention is not to be limited to the specific conditions or details described in these examples

10 Example 1

5

The purpose of this example was to evaluate the use of different types of surface modifiers for the preparation of an injectable nanoparticulate formulation of naproxen.

The study was conducted by screening eleven surface stabilizers to identify
the most suitable stabilizer for parenteral administration of naproxen. The
dispersions were formulated at 40% solids to 2.4% surface stabilizer.

TABLE 2

Surface Stabilizer	Manufacturer	Results
Plasdone C15 [®]	ISP Technologies,	size reduction < 400 nm
(polyvinylpyrrolidone)	Inc.	
Kollidon 17PF®	BASF Corp.	size reduction < 400 nm
(a polyvinylpyrrolidone		
polymer)		·
Povidone K30 [®]	ISP Technologies,	size reduction < 400 nm
(a polyvinylpyrrolidone	Inc.	
polymer)		
Tyloxapol	Nycomed, Inc.	size reduction > 400 nm
Pluronic F68 [®]	BASF Corp.	size reduction > 400 nm
(a high molecular weight		
polyoxyalkylene ether)		
Pluronic F108®	BASF Corp.	size reduction > 400 nm
(a high molecular weight		
polyoxyalkylene ether)		
Tween 80 [®]	ICI Americas	size reduction > 400 nm
(a polyoxyethylene sorbitan fatty		
acid ester)		
dioctylsulfosuccinate (CAS No.	Ashland Chem. Co.,	size reduction > 400 nm
577-11-7; aka Docusate Sodium)	Columbus, OH	
B20-5000 [©]	Dow Chemical	size reduction > 400 nm
(a triblock copolymer surface		
modifier)		
B20-5000-sulfonated	Dow Chemical	size reduction > 400 nm
(a triblock copolymer surface		
modifier)		1 100
lecithin (CAS No. 8002-43-5)	Ashland Chem. Co., Columbus, OH	size reduction > 400 nm
Povidone K30 [®] and Pluronic	ISP Technologies,	size reduction > 400 nm
F108 [®]	Inc. and BASF Corp.	

Only the use of the povidone polymers Plasdone C15[®], Povidone K30[®], and Kollidon 17PF[®] resulted in a nanoparticulate naproxen composition having an effective average particle size of less than about 400 nm.

5

Example 2

5

10

15

The purpose of this example was to determine the rates of absorption for intravenously and intramuscularly administered naproxen.

The plasma concentration of naproxen (µg/ml) in rabbits after administration of 15 mg/kg by either the IV or IM routes versus time in hours was determined. The method used for quantification of naproxen in rabbit plasma was modified from a procedure by Shimek et al., *Journal of Pharm. Sci.*, 15:436-439 (1982).

For IM administration, the mean peak plasma level concentration (C_{max}) of 45 \pm 9 µg/ml was reached at two hours. The absorption after IM injection was rapid with a mean plasma concentration of 23.5 \pm 5.1 µg/ml at 30 minutes after injection. At twelve hours post injection, plasma concentrations were still measurable at 5.2 \pm 3.4 µg/ml.

Pharmacokinetic Analysis: The area-under-curve value (AUC) (i.e., plasma -concentration time curve) calculations for the IM and IV routes were 287.1 μ g/ml • hr and 212.0 μ g/ml • hr, respectively. Mean clearance was calculated to be 3.4 ml/min after IM administration and 5.1 ml/min following IV administration. The calculated $T_{1/2}$ (the time period in which the maximum plasma concentration drops by half) following IM administration was 6.9 hours, and 7.0 hours following IV administration.

20

25

Example 3

The purpose of this example was to demonstrate the feasibility of using a Microfluidizer[®] for aseptically producing an injectable formulation of a naproxen colloidal dispersion.

A Microfluidizer[®], Model No. M110EH (Microfluidics Corp.), was successfully used to produce a sterile colloidal dispersion of naproxen suitable for injection. The naproxen slurry was heat sterilized prior to microfluidizing.

Example 4

5

10

15

20

25

The purpose of this example was to determine the potential local irritation of an injectable nanoparticulate naproxen formulation when administered intramuscularly to rats. This information correlates to the irritation or pain experienced upon administration of the formulation.

Test Formulation

Injectable nanoparticulate naproxen having a concentration of 489 mg/ml was used, comprising 489 mg/ml naproxen, 40 mg/ml of ISP PlasdoneTM C15, 1.9 mg/ml methylparaben (preservative), and 0.2 mg/ml propylparaben. Dosages of 49 and 134 mg/kg were administered intramuscularly. The intramuscular route was chosen because it is a possible route of administration to human. The test and control articles were stored at room temperature and protected from light.

Test animals

Twenty male Albino rats (Sprague-Dawley Crl:CD®) were used for the study, obtained from Charles River. The animals were laboratory bred and were experimentally naïve at the outset of the study. Animals selected for use were as uniform in age and weight as possible. they were approximately 7-8 weeks of age, and their body weights ranged from 210.7 to 247.0 gm. Each animal was identified by a unique number via an ear tag. All animals were acclimated to laboratory conditions for approximately 12 days prior to study initiation, and the animals were housed individually in stainless-steel cages.

PMI Feeds, Inc.®, Certified Rodent Chow was available ad libitum via food hoppers. No contaminants are known to be present in the certified diet that would interfere with the results of the study. Tap water was available ad libitum via automatic watering device or water bottle. The water was routinely analyzed for contaminants. No contaminants are known to be present in the water that would interfere with the results of the study.

All animals were kept in one room and with no additional studies or other species housed in the same room. The room was well ventilated (>10 air changes per hour) with 100% fresh air (no air recirculation). A 12-hour light/12-hour dark photoperiod was maintained. Room temperature and relative humidity were set to be maintained between 22±3°C and 40 to 70%, respectively.

Administration Protocol and Methods

5

10

15

The twenty test animals were assigned to treatment groups as shown in Table 3 below. Each animal received a single intramuscular injection of the test article and the vehicle in distinct previously shaven sites of contralateral legs: thigh muscle of the right and left hind legs, respectively. Prior to the day of dosing (designated Day 1 of the study), all animals were fasted overnight. Following dosing, animals were returned to their cages and subsequently provided with hoppers containing food. The animals were evaluated for changes in clinical signs and body weight and the injection sites were examined for any local reaction. Ten animals each were sacrificed at approximately 48 and 96 hours after the IM injection and the injection site areas removed and processed for histopathological examination.

	Table 3: Treatment Groups							
Group	Number of Males	Treatment	Dose (mg/kg)	Dose Vol. (ml/kg)	Day of Sacrifice			
1	5	Control	0	0.1	3			
:		Nanonaproxen	49	0.1				
2	5 .	Control	0	0.1	5			
	•	Nanonaproxen	49	0.1				
3	5	Control	0	0.275	3			
		Nanonaproxen	134	0.275				
4	5	Control	0	0.275	5			
•		Nanonaproxen	134	0.275				

Antemortem Procedures

5

Animals were observed once daily prior to dosing. During the study, each animal was observed once each morning and afternoon for changes in general appearance and behavior. In addition, the injection sites were examined daily thereafter for local reactions. The severity of any injection site observation was graded and if possible measured (length, width, and height). Body weights were measured prior to dosing and at sacrifice.

1. Clinical Observations and Mortality

Twice daily individual clinical observations are presented in Table 4. No animals died and no treatment-related clinical signs were seen in animals given 49 mg/kg of nanoparticulate naproxen by intramuscular injection. At a dose of 134 mg/kg/ treatment-related signs such as chromorhinorrhea, pallor, rough coat, and some chromodacryorrhea and brown staining were observed.

<u> </u>		Table 4: Clinical Observations
Test Article	Animal	Clinical Observations*
	No.	·
Nanoparticulate	311M	Days 1-3: normal
Naproxen;	312M	Days 1-3: normal
49 mg/kg	313M	Days 1-3: normal
For 3 day test	314M	Days 1-2: normal
period		Day 3: abrasion neck right side; stain red neck right side; scab scapula
		right
	315M	Days 1-3: normal
Nanoparticulate	321M	Days 1-5: normal
Naproxen;	322M	Days 1-5: normal
49 mg/kg	323M	Day 1: normal
		Day 2: slight bluish color at injection site 2
For 5 day test		Days 3-5: normal
period	324M	Days 1-4: normal
		Day 5: dehydrated; scab at injection site on right hind limb
	325M	Days 1-5: normal
Nanoparticulate	331M	Day 1: normal
Naproxen;		Days 2-3: infrequent stool
134 mg/kg		Day 3: chromorhinorrhea, pallor

		Table 4: Clinical Observations
Test Article	Animal	Clinical Observations*
	No.	
	332M	Day 1: normal
For 3 day test		Days 2-3: infrequent stool; chromorhinorrhea; pallor; rough coat
period		Day 3: chromodacryorrhea-both; brown-stained scrotum
	333M	Day 1: normal
1		Days 2-3: infrequent stool
		Day 3: chromorhinorrhea; pallor; dehydrated; scab at right injection
		site
	334M	Day 1: normal
]		Days 2-3: infrequent stool; chromorhinorrhea; wet coat pelvic region
		Day 3: pallor; scabs at both injection sites left and right hind limbs
İ	335M	Day 1: normal
Į		Days 2-3: infrequent stool
1	ļ	Day 3: chromodacryorrhea both; chromorhinorrhea; dehydrated;
		pallor; diarrhea; dark stool
Nanoparticulate	341M	Day I: normal
Naproxen;		Days 2-4: chromorhinorrhea
134 mg/kg	<u> </u>	Days 2-5: infrequent stool; pallor
	!	Day 3: brown-stained forefeet
For 5 day test		Days 3-5: rough coat
period		Day 4: prostrate
	342	Day 5: dehydrated; scab at injection sites on right hand limb Day 1: normal
	342	Day 2: chromorhinorrhea
İ		Days 2-3: infrequent stool
		Days 3-5: rough coat; pallor
		Days 4-5: scab head
		Day 5: scab at injection sites on left hand limb
	343M	Day 1: normal
	343111	Days 2-5: infrequent stool
		Days 3-5: piloerection; rough coat; dehydrated; pallor
····	344M	Day 1: normal
	3	Day 2: loose stool; chromorhinorrhea
		Days 2-3: infrequent stool
		Days 2-4: rough coat
		Day 5: scabs at injection sites bilaterally
	345M	Day 1: normal
		Days 2-5: infrequent stool; chromorhinorrhea; pallor
		Day 3: rough coat; chromodacryorrhea both
		Days 3-5: brown-stained forefeet
		Day 5: dehydrated; scabs at injection sites on hind limbs

*Findings exclude mechanical artifacts (clipper abrasions).

WO 00/09096

2. Body Weight

Individual and group mean body weights are presented in Table 5. The Day 3 low-dose group (49 mg/kg) was inadvertently not fasted for necropsy and, therefore, showed a much larger weight gain than the fasted low-dose group sacrificed on Day 5. However, animals in the high-dose group (134 mg/kg) sacrificed on Days 3 (also, inadvertently not fasted) or 5 showed an overall average weight loss that was considered to be treatment related.

Table 5: Individual and Group Mean Body Weights (g)							
Treatment	Animal	Day 1	Day 3*	Day 5			
	No.		•	·			
Nanoparticulate Naproxen;	311M	210.7	251.5				
49 mg/kg	312M	219.4	256.6				
-	313M	224.5	260.9				
	314M	234.7	271.8				
	315M	237.3	273.0				
	mean	225.3	262.8				
•	±SD	±11.0	±9.4				
Nanoparticulate Naproxen;	321M	218.9		233.5			
49 mg/kg	322M	216.8		222.4			
	323M	223.4		229.5			
	324M	234.6		249.1			
	325M	241.9		259.3			
	mean	227.1.		238.8			
	±SD	±10.8		±15.1			
Nanoparticulate Naproxen;	331M	215.2	203.2				
134 mg/kg	332M	216.6	210.1				
	333M	226.7	211.0				
	334M	228.0	216.3				
	335M	247.0	227.3				
	mean	226.7	213.6				
	±SD	±12.7	±9.0				
Nanoparticulate Naproxen;	341M	216.1		192.1			
134 mg/kg	342M	213.0		184.5			
-	343M	226.3		189.7			
	344M	228.3		208.5			
	345M	241.5		209.2			
	mean	225.0		196.8			
	±SD	±11.3		±11.3			

^{*}Terminal body weight from unfasted animals.

3. <u>Injection Site Evaluation</u>

Individual and group mean dermal irritation (erythema/eschar) and (edema) are presented in Tables 6 and 7, respectively. No erythema/eschar or edema responses were noted in any of the animals (indicated by "0" in Tables 6 and 7).

Scores								
Treatment	Animal	Day 2	Day 3	Day 4	Day 5			
	No.	·			•			
Control	311M	0	0					
	312M	0	0					
	313M	0	0					
	314M	0	0	1	·			
	315M	0	0	1				
	mean	0	0		~			
	±SD	±0	±0					
Nanoparticulate	311M	0	0					
Naproxen; 49 mg/kg	312M	0	0					
	313M	0	0	1				
	314M	0	0					
	315M	0	0					
	mean	0	0					
	±SD	±0	±0	1				
control	321M	0	0	0	0			
	322M	0	0	0	0			
ĺ	323M	0	0	0	0			
	324M	0 j	0	0	0			
	325M	0 !	0	0	. 0			
	mean	0	0	0	0			
	±SD	±0	±0	±0	±0			
Nanoparticulate	321M	0	0	0	0			
Naproxen; 49 mg/kg	322M	0	0	0	0			
	323M	0	0	0	0			
	324M	0	0	0	0			
[325M	0	0	0	0			
ſ	mean	0	0	0	0			
	±SD	±0	±0	±0	±0			
Control	331M	0	0					
	332M	Q	0					
[333M	0	0					
	334M	0	0					
	335M	0	0					

Table 6: Indiv	idual and G			(Erythema c	r Eschar)				
	Scores								
Treatment	Animal	Day 2	Day 3	Day 4	Day 5				
	No.								
	mean	0	0						
	±SD	±0	±0						
Nanoparticulate	331M	0	0						
Naproxen;	332M	0	0						
134 mg/kg	333M	0	0						
	334M	0	0						
	335M	0	0		······································				
	mean	0	0						
	±SD	±0	±0						
control	341M	0	0	0	0				
•	342M	0	0	0	0				
	343M	0	0	0	0				
	344M	0	0	0	0				
	345M	0	0	0	0				
	mean	0	0	0	0				
	±SD	±0	±0	±0	±0				
Nanoparticulate	341M	0	0	0	0				
Naproxen;	342M	0	0	0	0				
134 mg/kg	343M	0	0	0	0.				
•	344M	0 .	0	0	0				
	345M	0	0	0	· 0				
	mean	0	0	0	0				
	±SD	±0	±0	±0	±0				

Table 7: Indivi	dual and Group M	lean Dermal	Irritation (Ed	dema) Sco	res
Treatment	Animal No.	Day 2	Day 3	Day 4	Day 5
Control	311M	0	0		
	312M	0	0		
	313M	0	0		
	314M	0	0		
	315M	0	0		
	mean	0	0		
	±SD	±0	_ ±0		
Nanoparticulate	311M	0	0		
Naproxen; 49 mg/kg	312M	0	0		
	313M	0	0		
	314M	0	0		
	315M	0	0		
	mean	0	0		
	±SD	±0	±0		

Treatment	Animal No.	Day 2	Day 3	Day 4	Day 5
Control	321M	0	0	0	0
•	322M	0	0	0	0
	323M	0	0	0	0
,	324M	0	0 ·	0	0
	325M	0	0	0	0
	mean	0	0	0	0
•	±SD	±0	±0	±0	±0
Nanoparticulate	321M	0	0	0	0
Naproxen; 49 mg/kg	322M	0	0	0	0
	323M	0	0	0	0
	324M	0	0	0	0
	325M	0	0	0	0
	mean	0	0	0	0
	±SD	±0	±0	±0	±0
control	331M	0	0		-
	332M	0	0		
	333M	0	0		
	334M	0	0		
	335M	0	0	· · ·	
	mean	0	0		
	±SD	±0	±0		
Nanoparticulate	331M	0	0		
Naproxen;	332M	0	0		
134 mg/kg	333M	0	0		
	334M	0	0		
	335M	0	0		
	mean	0	0		
	±SD	±0	±0		
control	341M	0	0	.0	0
	342M	0	0	0	0
	343M	0	0	0	0
	344M	0	0.	0	0
	345M	0	0	0	0
	mean	0	0	0	0
	±SD	±0	±0	±0	±0
Nanoparticulate	341M	0	0	0	0
Naproxen;	342M	0	0	0	0
134 mg/kg	343M	0	0	0	0
	344M	0	0	0	0
	345M	0	0	0	0
	mean	0	0	0	0
	±SD	±0	±0	±0	±0

Postmortem Procedures

All animals were terminated by CO₂ asphyxiation and exsanguination. Gross necropsy was limited to examination of the injection sites. No treatment-related effects were observed as all injection sites (muscle) were normal. One animal (#333) had a single red subcutaneous focus above the muscle injection site that probably corresponded to hemorrhage. Injection site scabs noted on the twice daily clinical observations generally corresponded to dried blood. Although no internal gross examination was performed, two high-dose animals (#'s 332 and 333) were observed to have severely distended stomachs filled with fluid and gas when they were terminated by exsanguination. These observed findings were considered to be treatment related.

Conclusion

5

10

15

20

25

No dermal irritation was observed following single-dose intramuscular administration of injectable nanoparticulate naproxen at doses of 49 mg/kg and 134 mg/kg, in comparison to the control animals. Similarly, no treatment-related clinical signs were observed at doses of 49 mg/kg. At a dose of 134 mg/kg, the following clinical signs were observed: chromorhinorrhea, pallor, rough coat, some chromodacryorrhea, and brown staining.

At necropsy, no treatment-related gross findings at the injection sites were observed. Similarly, histopathological examination of the injection sites revealed no treatment-related effects.

* * * * *

It will be apparent to those skilled in the art that various modifications and variations can be made in the compositions, methods, and uses of the present invention without departing from the spirit or scope of the invention. Thus, it is intended that the present invention cover the modifications and variations of this

invention provided they come within the scope of the appended claims and their equivalents.

WE CLAIM:

5

10

1. An injectable pharmaceutical composition comprising: (1) naproxen particles having an effective average particle size of less than about 600 nm; (2) a povidone polymer adsorbed on the surface of the naproxen particles; and (3) a pharmaceutically acceptable carrier.

- 2. The composition of claim 1, wherein the effective average particle size of the naproxen particles is less than about 450 nm.
- 3. The composition of claim 1, wherein the effective average particle size of the naproxen particles is selected from the group consisting of less than about 400 nm, less than about 300 nm, less than about 250 nm, and less than about 100 nm.
- 15 4. The composition of claim 1, wherein the povidone polymer is present in an amount of about 0.1 to about 50% (w/w) based on the total weight of the naproxen and povidone polymer.
- 5. The pharmaceutical composition of claim 1, wherein the povidone polymer has a molecular weight of about 40,000 daltons.
 - 6. The pharmaceutical composition of claim 1, wherein the povidone polymer has a molecular weight of less than about 40,000 daltons.
- 7. The composition of claim 1, wherein the naproxen is present in an amount of about 5.0 to about 50% (w/w), by weight.

8. A method of treating a mammal comprising administering to the mammal an effective amount of an injectable pharmaceutical composition comprising: (1) naproxen particles having an effective average particle size of less than about 600 nm; (2) a povidone polymer adsorbed on the surface of the naproxen particles; and (3) a pharmaceutically acceptable carrier.

- 9. The method of claim 8, wherein the effective average particle size of the naproxen particles is less than about 450 nm.
- 10. The method of claim 9, wherein the effective average particle size of the naproxen particles is selected from the group consisting of less than about 400 nm, less than about 300 nm, less than about 250 nm, and less than about 100 nm.
- 11. The method of claim 8, wherein the povidone polymer has a molecular weight of about 40,000 daltons.

5

- 12. The method of claim 8, wherein the povidone polymer has a molecular weight of less than about 40,000 daltons.
- 20 13. A method of preparing an injectable pharmaceutical composition that produces minimal or no pain or irritation upon administration, wherein the composition comprises: (1) naproxen particles having an effective average particle size of less than about 600 nm; (2) a povidone polymer adsorbed on the surface of the naproxen particles; and (3) a pharmaceutically acceptable carrier, wherein the method comprises:
 - (a) dispersing the naproxen particles in a liquid dispersion medium comprising a povidone polymer; and

PCT/US99/18270

- (b) mechanically reducing the particle size of the naproxen to an effective average particle size of less than about 600 nm.
- 14. The method of claim 13, wherein the effective average particle size of the naproxen particles is less than about 450 nm.
 - 15. The method of claim 14, wherein the effective average particle size of the naproxen particles is selected from the group consisting of less than about 400 nm, less than about 300 nm, less than about 250 nm, and less than about 100 nm.

10

25

- 16. The method of claim 13, wherein the povidone polymer has a molecular weight of about 40,000 daltons.
- 17. The method of claim 13, wherein the povidone polymer has a molecular weight of less than about 40,000 daltons.
- 18. A method of preparing an injectable pharmaceutical composition comprising: (1) naproxen particles having an effective average particle size of less than about 600 nm; (2) a povidone polymer adsorbed on the surface of the naproxen particles; and (3) a pharmaceutically acceptable carrier, wherein the method comprises:
 - (a) dispersing the naproxen particles in a liquid dispersion;
 - (b) mechanically reducing the particle size of the naproxen to an effective average particle size of less than about 600 nm; and
 - (c) adding a povidone polymer to the dispersion of naproxen particles.
 - 19. The method of claim 18, wherein the effective average particle size of the naproxen particles is less than about 450 nm.

PCT/US99/18270

20. The method of claim 19, wherein the effective average particle size of the naproxen particles is selected from the group consisting of less than about 400 nm, less than about 300 nm, less than about 250 nm, and less than about 100 nm.

5

WO 00/09096

- 21. The method of claim 18, wherein the povidone polymer has a molecular weight of about 40,000 daltons.
- The method of claim 18, wherein the povidone polymer has a molecular weight of less than about 40,000 daltons.

INTERNATIONAL SEARCH REPORT

Intel onal Application No PCT/US 99/18270

A c. LASSIFICATION OF SULPLET MATER THE TECT AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGIKS/11 AGI									
Representation searched (classification system followed by disselfication symbols) The Post of ASTA	A. CLASS IPC 7	FICATION OF SUBJECT MATTER A61K9/51 A61K31/192 A61K9/10	0						
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched	According t	o International Patent Classification (IPC) or to both national classific	eation and IPC						
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Commonstrate									
Electronic data base consulted during the International search (name of data base and, where practical, search terms used) C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Catation of document, with indication, where appropriate, of the relevant passages Refevant to claim No. X	IPC 7	A61K							
C. DOCUMENTS CONSIDERED TO BE RELEVANT Catagory* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. X US 5 510 118 A (BOSCH ET AL.) 23 April 1 1996 (1996–04–23) column 3, line 65 -column 4, line 26 column 9; table 1 A EP 0 577 215 A (STERLING MINTHORP INC.) 5 January 1994 (1994–01–05) page 2, line 1 - line 32 page 11; example 17 A EP 0 463 228 A (ALFA WASSERMANN S.P.A.) 2 January 1992 (1992–01–02) claim 1 A GB 2 046 094 A (A. NATTERMANN & CIE GMBH) 12 November 1980 (1980–11–12) page 2; example 3 claims 1–10 Further documents are listed in the continuation of box C. *Special categories of claed documents: ** document defining the general state of the art which is not considered to be of particular relevance which is older to establish the publication of another claim or other special reason (as specified) ** document defining the general state of the art which is not considered to be of particular relevance which is older to establish the publication of another claim or other special reason (as specified) ** document of particular relevance; the claimed invention which is older to establish the publication or other special reason (as specified) ** document of particular relevance; the claimed invention which is older to establish the publication or other special reason (as specified) ** document of particular relevance; the claimed invention and the principle or theory underlying the winering of another claimed invention and the principle or theory underlying the three which is older to establish the publication or other special reason (as specified) ** document of particular relevance; the claimed invention and the principle or theory underlying the document is active and only in the principle or theory underlying the winering of a particular relevance is the definition or other special reason (as specified) ** document of particular relevance; the claimed invention in the art. ** document of particular relevance is the definition or other th									
Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. X US 5 510 118 A (BOSCH ET AL.) 23 April 1996 (1996–04–23) column 3, line 65 –column 4, line 26 column 9; table 1 A EP 0 577 215 A (STERLING WINTHORP INC.) 5 January 1994 (1994–01–05) page 2, line 1 – line 32 page 11; example 17 A EP 0 463 228 A (ALFA WASSERMANN S.P.A.) 2 January 1992 (1992–01–02) claim 1 A GB 2 046 094 A (A. NATTERMANN & CIE GMBH) 12 November 1980 (1980–11–12) page 2; example 3 claims 1–10 Further documents are listed in the continuation of box C. *Special categories of cited documents: **Special categories of cited documents: **Special categories of cited of cellular relevance **C* document defining the general state of the art which is not considered to be of particular relevances (as specified) **Of document relevance in the publication date of another citation or other pecial reason (as specified) **Of document published prior to the informational filing date but later than the priority date detained **Of document published prior to the informational filing date but later than the priority date detained **December 1999 Name and mailing address of the ISA **U, -220 bit V filiprily Tel. (431-70) 340-2400, Tr. 3 16-55 ppp nl. **December 1999 Name and mailing address of the ISA **U, -220-01 bit V filiprily Tel. (431-70) 340-2400, Tr. 3 16-55 ppp nl. **Boars K	Electronic data base consulted during the international search (name of data base and, where practical, search terms used)								
X				T					
23 April 1996 (1996–04-23) column 3, line 65 -column 4, line 26 column 9; table 1 A EP 0 577 215 A (STERLING WINTHORP INC.) 1-22 5 January 1994 (1994–01–05) page 2, line 1 - line 32 page 11; example 17 A EP 0 463 228 A (ALFA WASSERMANN S.P.A.) 1-22 Claim 1 A GB 2 046 094 A (A. NATTERMANN & CIE GMBH) 1-22 I November 1980 (1980–11–12) page 2; example 3 claims 1-10 Further documents are listed in the continuation of box C. X Patent family members are fisted in annex. *Special categories of cited documents: A document of elining the general state of the art which is not considered to be of particular relevance E earlier document but published on or after the international lifting date 1 document of particular relevance; the claimed invention cannot be considered to or document of the restoration or other special reason (as specified) T document of particular relevance; the claimed invention cannot be considered to be of particular relevance; the claimed invention cannot be considered to be of particular relevance; the claimed invention cannot be considered to be considered to be considered to be of particular relevance; the claimed invention cannot be considered to be considered to be considered to be considered to be considered to be considered to be considered to be considered to be considered to be considered to be considered to be considered to be considered to be considered to be considered to be considered to be considered to be considered to be considered to be considered to be considered to be considered to be considered to be considered to be considered to be considered to be considered to be considered to be considered to be considered to be considered to be considered to be considered to be considered to be considered to be considered to be considered to be considered to be considered to be considered to be considered to be considered to be considered to be considered to be considered to be considered to be considered to be considered to be considered to be considered to be considered to be c	Category *	Citation of document, with indication, where appropriate, of the rel	levant passages	Relevant to claim No.					
5 January 1994 (1994–01–05) page 2, line 1 – line 32 page 11; example 17 A EP 0 463 228 A (ALFA WASSERMANN S.P.A.) 1–22 2 January 1992 (1992–01–02) claim 1 A GB 2 046 094 A (A. NATTERMANN & CIE GMBH) 1–22 12 November 1980 (1980–11–12) page 2; example 3 claims 1–10 Further documents are listed in the continuation of box C. X Patent family members are listed in annex. *Special categories of cited documents: A document defining the general state of the art which is not considered to be of particular relevance *Fe earlier document but published on or after the international fling date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention varied is clot to establish the publication date of another valid or other special reason (as specified) **Of document releving to an oral disclosure, use, exhibition or other repeats of the international fling date but later than the priority date prior to the international fling date but later than the priority date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered to invention and invention or other special reason (as specified) **Of document published prior to the international fling date but later than the priority date of the sactor of particular relevance; the claimed elivention cannot be considered to involve an inventive step when the document is combined when or more other such document is combined when or more other such document is combined when or more other such document is combined when or more other such document is combined when or more other such document is combined when or more other such document is combined when or more other such document is combined when or or more other such document is combined when or or more other such document is combined when the considered to involve an inventive step when the document is combined when or or more other such document is combined whe	X	23 April 1996 (1996-04-23) column 3, line 65 -column 4, line	⊋ 26	1-22					
2 January 1992 (1992–01–02) claim 1 A GB 2 046 094 A (A. NATTERMANN & CIE GMBH) 1-22 Page 2; example 3 claims 1–10 Further documents are listed in the continuation of box C. Special categories of cited documents: 'A' document defining the general state of the art which is not considered to be of particular relevance in the document billing date or priority date and not in conflict with the application but clad to understand the principle or theory underfying the members are listed in annex. 'T' later document published after the international filing date or priority date and not in conflict with the application but clad to understand the principle or theory underfying the members. 'T' later document published after the international filing date or priority date and not in conflict with the application but clad to understand the principle or theory underfying the members. 'Y document referring to an oral disclosure, use, exhibition or other special reason (as specified) 'O' document referring to an oral disclosure, use, exhibition or other means 'P' document referring to an oral disclosure, use, exhibition or other means 'P' document published prior to the international filing date but later than the priority date claimed 'D' document published prior to the international filing date but later than the priority date claimed 'D' document published prior to the international filing date but later than the priority date claimed 'D' document published prior to the international filing date but later than the priority date claimed 'D' document published prior to the international search eport 12/01/2000 Authorized officer Page 7 K	A	5 January 1994 (1994-01-05) page 2, line 1 - line 32	PINC.)	1-22					
Truther documents are listed in the continuation of box C. X Patent family members are listed in annex.	А	2 January 1992 (1992-01-02)	1-22						
*Special categories of cited documents: *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *C* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed *Date of the actual completion of the international search *December 1999 *Name and mailing address of the ISA *European Patent Office, P.B. 5818 Patentlaan 2 *NL - 2280 HV Rijswijk *Tet. (-431-70) 340-2040, Tx. 31 651 epo nl. *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention in conflict with the application but cited to understand the principle or theory underlying the published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered to cannot be considered to another cannot be considered to involve an inventive step when the document is combined with one or more other such documents is combined with one or more other such documents is combined with one or more other such documents is combined with one or more other such documents is combined with one or more other such documents is combined with one or more other such documents is combined with one or more other such documents is combined with one or more other such documents is combined with one or more other such documents is combined with one or more other such documents is combined with one or more other such documents is combined with one or more other such documents is combined with one or more other such docu	Α	12 November 1980 (1980-11-12) page 2; example 3	CIE GMBH)	1-22					
"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "P" document published prior to the international filing date but later than the priority date claimed "Date of the actual completion of the international search Date of the actual completion of the international search PAD December 1999 Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040. Tx. 31 651 epo nl,	Further documents are listed in the continuation of box C. Patent family members are listed in annex.								
"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search 21 December 1999 Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,	* Special categories of cited documents :								
Considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which cated to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date dairned Date of the actual completion of the international search 21 December 1999 Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,		ent defining the general state of the art which is not	or priority date and not in conflict with	the application but					
Turned date "United the second comment which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "Date of the actual completion of the international search "Date of the actual completion of the international search "A" document member of the same patent family Date of mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl. "A" document of particular relevance; the claimed in when the document is taken alone who the document is taken alone who the document is taken alone who the document is taken alone when the document is taken alone who the document is taken alone who the document is taken alone who the document is taken alone who the document is taken alone who the document is taken alone who the document is taken alone who the document is taken alone who the document is taken alone who the document is taken alone who the document is taken alone who the document is taken alone who the document is taken alone who the document is taken alone who the document is taken alone who the document is taken alone who the document is taken alone who the document is taken alone who the document is taken alone who the document is taken alone who the document is taken alone who the document is taken alone who the document is taken alone who the document is taken alone who the document is taken alone who the document is taken alone who the document is taken alone who the document is taken alone who the document is taken alone who the document is taken alone who the document is taken alone who the document is taken alone who the document is taken alone who the document is taken alone who the document is taken alone who the document is taken alone who the document	considered to be of particular relevance invention								
which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search 21 December 1999 Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,	ning date cannot be considered novel or cannot be considered to								
O document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filling date but later than the priority date claimed *Date of the actual completion of the international search 21 December 1999 Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040. Tx. 31 651 epo nl. *A document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *& document member of the same patent family Date of mailing of the international search report 12/01/2000 Authorized officer	which is cited to establish the publication date of another Y document of particular relevance; the claimed invention								
Date of the actual completion of the international search 21 December 1999 Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040. Tx. 31 651 epo nl.	"O" document referring to an oral disclosure, use, exhibition or other means document is combined with one or more other such document other means. Such combination being obvious to a person skilled								
21 December 1999 12/01/2000 Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040. Tx. 31 651 epo nl, Ronz K		r document backeted buck to the interventional limit data out							
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31-70) 340–2040. Tx. 31 651 epo nl,	Date of the	actual completion of the international search	Date of mailing of the international sea	arch report					
European Patent Office, P.B. 5818 Patentiaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040. Tx. 31 651 epo nl,	2	l December 1999	12/01/2000						
	Name and n	European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk	Authorized officer Benz, K						

INTERNATIONAL SEARCH REPORT

In...mational application No.

PCT/US 99/18270

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority. namely: Remark: Although claims 8-12 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims: It is covered by claims Nos.:
Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

information on patent family members

Inte: onal Application No
PCT/US 99/18270

	tent document in search report		Publication date	ı	Patent family member(s)	Publication date
US	5510118	Α	23-04-1996	UA WO	4867396 A 9625152 A	04-09-1996 22-08-1996
 EP	577215	 А	05-01-1994	U\$	5399363 A	21-03-1995
				AU	675432 B	06-02-1997
			• •	· AU	4156093 A	06-01-1994
				CA	2098242 A	02-01-1994
				CN	1084391 A	30-03-1994
				CZ	9301316 A	16-02-1994
				FI	933040 A	02-01-1994
				HU	64832 A	28-03-1994
				JP MV	7165562 A 9303950 A	27-06-1995 31-01-1994
				. MX NO	9303950 A 932403 A	03-01-1994
				NZ	248042 A	26-10-1994
				SG	55089 A	21-12-1998
				SK	68193 A	02-02-1994
				US	5494683 A	27-02-1996
EP	463228	Α	02-01-1992	IT	1242642 B	16-05-1994
				AU	627639 B	27-08-1992
				AU	6769190 A	24-10-1991
				CA	2031994 A	18-10-1991
				JP	4005230 A	09-01-1992
				NZ PT	236356 A 96263 A	27-01-1993 31 - 10-1991
			•	ÜS	5096926 A	17-03-1992
				US	5128373 A	07-07-1992
GB	2046094	Α	12-11-1980	DE	2914788 A	16-10-1980
				AT	369651 B	25-01-1983
			•	AU	539044 B	06-09-1984
				AU	5733180 A 882731 A	16-10-1980 31-07-1980
	•			BE CA	1144480 A	12-04-1983
				CH	642546 A	30-04-1984
				FR	2453644 A	07-11-1980
				ΙΤ	1148790 B	03-12-1986
				ĴP	1671396 C	12-06-1992
				JP	3037524 B	05-06-1991
				JP	55141407 A	05-11-1980
				NL	8002097 A	14-10-1980
				SE	451427 B	12-10-1987
				SE	8002714 A	12-10-1980
				US	4309421 A	05-01-1982
				ZA	8002157 A	27-05-1981